ICYMI, some of this week’s featured content includes practice management tips, SGT-510 for psoriasis, July skin care, plus more.
This week’s edition of The Mainstream Patient features stories about eyelid eczema, biologics, jojoba oil for acne, plus more.
A study in the Journal of Drugs in Dermatology gathered a panel of skin of color experts to examine acne treatment in patients with skin of color.
With in-person conferences coming out of the shadows and into the light once again, we detail a guide to Aesthetics Biomedical’s “Perspectives. The Evolution of Aesthetics” symposium happening July 24.
The Dermatologic Surgery journal published a study on who performs cosmetic injections at dermatology and plastic surgery practices.
Each month, Dermatology Times® features a roundup of products trending in skin care. Click here to find out what products are trending for the month of July.
The fully human monoclonal antibody is currently approved in more than 60 countries.
Patients on placebo with a history of systemic non-steroidal immunosuppressants generally fared worse than their treatment-naïve counterparts.
Investigators show that both terms tend to be used in different contexts within the biomedical literature.
July marks the 1 year anniversary since the launch of The Cutaneous Connection Podcast. Check out what episodes were the most popular here.
Sol-Gel has announced pre-clinical data on SGT-510, its roflumilast drug, for the treatment of psoriasis.
The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma.
Looking to get your practice ahead of the rest post-COVID-19? These 10 practical practice management tips will help you jump start your practice into the future.